Revenue has been highly erratic, falling from $46.3M in 2024Q3 to $1.8M in 2026Q3, while operating margin stayed negative at -7.3% in the latest quarter and gross margin ranged from -31.6% to 136.3%, suggesting margins are unanchored by a stable revenue base.
Kyntra Bio, Inc. (KYNB) annual income statement — 14-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Sales/Revenue | 5.3M | 6.44M | 29.62M | 46.8M | 140.73M | 235.31M | 176.32M | 256.58M | 212.96M | 125.67M | 179.58M | 180.83M | 137.6M | 102.17M | 65.93M |
| Revenue Growth % | 104.49% | -78.26% | -36.71% | -66.74% | -40.19% | 33.46% | -31.28% | 20.48% | 69.46% | -30.02% | - | 31.41% | 34.68% | 54.96% | - |
| Cost of Goods Sold | 3.65M | 556K | 15.56M | 3.96M | 20.28M | 449.19M | 8.87M | 1.15M | 235.84M | 196.52M | 187.21M | 214.09M | 150.79M | 85.71M | 74.22M |
| COGS % of Revenue | - | 8.63% | 52.53% | 8.47% | 14.41% | 190.89% | 5.03% | 0.45% | 110.74% | 156.38% | 104.25% | 118.39% | 109.59% | 83.89% | 112.57% |
| Gross Profit | -104K | 5.88M | 14.06M | 42.84M | 120.45M | -213.88M | 167.45M | 255.43M | -22.88M | -70.85M | -7.63M | -33.26M | -13.19M | 16.46M | -8.29M |
| Gross Margin % | -1.96% | 91.37% | 47.47% | 91.53% | 85.59% | -90.89% | 94.97% | 99.55% | -10.74% | -56.38% | -4.25% | -18.39% | -9.59% | 16.11% | -12.57% |
| Gross Profit Growth % | - | -58.15% | -67.18% | -64.43% | 156.32% | -227.73% | -34.44% | 1216.34% | 67.7% | -828.68% | - | -152.11% | -180.15% | 298.58% | - |
| Operating Expenses | 59.38M | 51.78M | 164.48M | 365.56M | 421.48M | 74.65M | 359.33M | 344.74M | 299.65M | 248.28M | 233.23M | 258.45M | 187.7M | 110.12M | 93.16M |
| OpEx % of Revenue | - | 804.02% | 555.27% | 781.07% | 299.49% | 31.72% | 203.8% | 134.36% | 140.71% | 197.57% | 129.88% | 142.93% | 136.41% | 107.78% | 141.29% |
| Selling, General & Admin | 28.88M | 27.71M | 49.33M | 86.48M | 124.69M | 109.12M | 106.41M | 135.48M | 63.81M | 51.76M | 46.02M | 44.36M | 36.91M | 24.41M | 18.93M |
| SG&A % of Revenue | - | 430.26% | 166.54% | 184.78% | 88.6% | 46.37% | 60.35% | 52.8% | 29.96% | 41.19% | 25.63% | 24.53% | 26.82% | 23.89% | 28.72% |
| Research & Development | 29.92M | 23.52M | 95.69M | 266.47M | 296.79M | 387.04M | 252.92M | 209.26M | 235.84M | 196.52M | 187.21M | 214.09M | 150.79M | 85.71M | 74.22M |
| R&D % of Revenue | - | 365.17% | 323.05% | 569.35% | 210.89% | 164.48% | 143.45% | 81.56% | 110.74% | 156.38% | 104.25% | 118.39% | 109.59% | 83.89% | 112.57% |
| Other Operating Expenses | 586K | 553K | 19.45M | 12.61M | 0 | -421.51M | 0 | 0 | 42.16M | 0 | 0 | 0 | 16K | 156K | 181K |
| Operating Income | -58.33M | -45.9M | -150.42M | -322.72M | -301.02M | -288.53M | -191.88M | -89.31M | -86.69M | -122.61M | -53.65M | -77.63M | -50.1M | -7.95M | -27.22M |
| Operating Margin % | -1099.92% | -712.66% | -507.8% | -689.53% | -213.9% | -122.62% | -108.83% | -34.81% | -40.71% | -97.57% | -29.88% | -42.93% | -36.41% | -7.78% | -41.29% |
| Operating Income Growth % | - | 69.49% | 53.39% | -7.21% | -4.33% | -50.37% | -114.84% | -3.02% | 29.29% | -128.52% | - | -54.93% | -530.29% | 70.8% | - |
| EBITDA | -58.31M | -45.15M | -147.72M | -312.79M | -290.42M | -273.72M | -169.83M | -67.86M | -80.13M | -116.51M | -47.61M | -71.95M | -45.63M | -2.87M | -21.63M |
| EBITDA Margin % | -1099.53% | -701.04% | -498.71% | -668.31% | -206.36% | -116.32% | -96.32% | -26.45% | -37.63% | -92.71% | -26.51% | -39.79% | -33.16% | -2.8% | -32.8% |
| EBITDA Growth % | 52.36% | 69.44% | 52.77% | -7.7% | -6.1% | -61.17% | -150.27% | 15.31% | 31.22% | -144.7% | - | -57.67% | -1492.74% | 86.75% | - |
| D&A (Non-Cash Add-back) | 21K | 748K | 2.69M | 9.93M | 10.6M | 14.81M | 22.05M | 21.45M | 6.56M | 6.1M | 6.04M | 5.68M | 4.47M | 5.08M | 5.6M |
| EBIT | -83.15M | -58.29M | -145.12M | -315.13M | -293.43M | -348.53M | -186.33M | -73.77M | -75.13M | -110.85M | -51.03M | -74.5M | -48.4M | -4.24M | -22.64M |
| Net Interest Income | -3.15M | -5.82M | -2.95M | -501K | 6.16M | -1.07M | 3.15M | 12.67M | 577K | -3.27M | -8.1M | -7.91M | -9.4M | -6.99M | -5.63M |
| Interest Income | 4.06M | 2.94M | 5.3M | 7.59M | 7.6M | 0 | 5.55M | 15.55M | 11.57M | 6.43M | 2.63M | 3.12M | 1.69M | 3.71M | 4.4M |
| Interest Expense | 5.57M | 8.76M | 8.25M | 8.1M | 1.44M | 1.07M | 2.4M | 2.88M | 10.99M | 9.71M | 10.72M | 11.03M | 11.11M | 10.7M | 10.03M |
| Other Income/Expense | 40.72M | -12.4M | -2.95M | -501K | 7.73M | -1.15M | 2.95M | 12.67M | 577K | -3.27M | -8.1M | -7.91M | -9.4M | -6.99M | -5.45M |
| Pretax Income | -17.61M | -58.29M | -153.37M | -323.22M | -293.3M | -289.68M | -188.93M | -76.64M | -86.12M | -125.88M | -61.75M | -85.54M | -59.5M | -14.94M | -32.67M |
| Pretax Margin % | -332.1% | -905.19% | -517.76% | -690.6% | -208.4% | -123.1% | -107.15% | -29.87% | -40.44% | -100.17% | -34.39% | -47.3% | -43.24% | -14.63% | -49.55% |
| Income Tax | -1K | -90K | -269K | -252K | 358K | 347K | 360K | 328K | 304K | 321K | -71K | 242K | 0 | 0 | -100K |
| Effective Tax Rate % | 0.01% | 0.15% | 0.18% | 0.08% | -0.12% | -0.12% | -0.19% | -0.43% | -0.35% | -0.26% | 0.11% | -0.28% | 0% | 0% | 0.31% |
| Net Income | 34.88M | 183.45M | -47.58M | -284.23M | -293.65M | -290.02M | -189.29M | -76.97M | -86.42M | -126.2M | -61.68M | -85.78M | -59.5M | -14.94M | -32.57M |
| Net Margin % | 657.67% | 2848.63% | -160.63% | -607.29% | -208.66% | -123.25% | -107.36% | -30% | -40.58% | -100.43% | -34.35% | -47.44% | -43.24% | -14.63% | -49.4% |
| Net Income Growth % | -78.67% | 485.57% | 83.26% | 3.21% | -1.25% | -53.22% | -145.93% | 10.94% | 31.52% | -104.61% | - | -44.16% | -298.21% | 54.12% | - |
| Net Income (Continuing) | -17.61M | -58.2M | -153.1M | -322.97M | -293.65M | -290.02M | -189.29M | -76.97M | -86.42M | -120.88M | -61.68M | -85.78M | -59.5M | -14.94M | -32.57M |
| Discontinued Operations | 1000K | 241.66M | 105.52M | 38.74M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 21.48M | 34.51M | 41.97M | 41.97M | 19.97M | 19.97M | 19.27M | 19.27M | 19.27M | 19.27M | 19.27M | 19.27M | 19.27M | 27.88M | 27.7M |
| EPS (Diluted) | 8.61 | 45.37 | -11.89 | -73.03 | -78.45 | -78.51 | -2.11 | -0.89 | -1.03 | -1.73 | -0.98 | -1.42 | -1.04 | -0.32 | -2.47 |
| EPS Growth % | 1557.69% | 481.58% | 83.72% | 6.91% | 0.08% | -3620.85% | -137.08% | 13.59% | 40.46% | -76.53% | - | -36.54% | -225% | 87.04% | - |
| EPS (Basic) | - | 45.37 | -11.89 | -73.03 | -78.45 | -78.51 | -2.11 | -0.89 | -1.03 | -1.73 | -0.98 | -1.42 | -1.04 | -0.32 | -2.47 |
| Diluted Shares Outstanding | 4.05M | 4.04M | 4M | 3.89M | 3.74M | 3.69M | 3.59M | 3.47M | 3.36M | 2.92M | 2.51M | 60.34M | 57.43M | 47.27M | 13.17M |
| Basic Shares Outstanding | 4.05M | 4.04M | 4M | 3.89M | 3.74M | 3.69M | 3.59M | 3.47M | 3.36M | 2.92M | 2.51M | 60.34M | 57.43M | 47.27M | 13.17M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying KYNB stock.
For fiscal year 2025, Kyntra Bio, Inc. (KYNB) reported total revenue of $6.4M. This represents a 90.2% decline compared to $65.9M in 2012.
Kyntra Bio, Inc. (KYNB) is profitable, generating $183.5M in net income for the fiscal year ending 2025 with a net profit margin of 2848.6%.
Kyntra Bio, Inc. (KYNB) reported an operating income of $-45.9M, resulting in an operating profit margin of -712.7%. This margin reflects the operational efficiency of the business before interest and taxes.
Kyntra Bio, Inc. (KYNB) generated $5.9M in gross profit for the year, representing a gross profit margin of 91.4%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Volatile quarterly revenue base
Metrics are mathematically derived from official filings.
Revenue Base Too Erratic for Trend Read
Based on the reported quarterly figures, KYNB's revenue swung from $46.3M in 2024Q3 to roughly $1.8M in 2026Q3, making any sustained growth trajectory difficult to establish from this income statement.
The sharp decline from the 2024 quarters to a sub-$4M run-rate suggests the prior revenue was either non-recurring or tied to a discrete event rather than a repeatable commercial base. Quarter-over-quarter growth readings swing between triple-digit gains and steep contractions, which points to lumpy recognition rather than durable demand. Investors should monitor whether the recent $1.3M to $3.7M band stabilizes before attributing any growth durability to the business.
Gross Margin Unanchored by Revenue Scale
As reported in the income statement, KYNB's gross margin has ranged from negative 31.6% to 136.3% across the periods shown, reflecting cost-of-revenue figures that move independently of a stable revenue base.
Gross margin readings this volatile are better interpreted as a product of small and irregular revenue denominators than as evidence of pricing power or structural cost advantage. Peers such as AKBA and PTCT report gross margins above 80%, a benchmark that KYNB has not consistently approached on a reported basis. Until revenue and cost of revenue move in a more predictable relationship, the margin profile warrants further investigation rather than a durable conclusion.
Operating Losses Persist Despite Cost Control
Based on reported figures, KYNB's operating margin remained negative in most periods, with R&D and SG&A consistently absorbing more than the gross profit generated, leaving operating income deeply negative.
The inability of gross profit to cover R&D and SG&A indicates that the cost base is not yet scaling against the revenue line, which is the opposite of positive operating leverage. Operating losses near $13.8M to $17.6M across recent quarters suggest the company remains in a investment-heavy phase. This raises the question of how long current spending can continue without a meaningful step-up in recognized revenue.
Net Income Dominated by Non-Operating Swings
According to the reported income statement, KYNB's net income diverges sharply from operating results, with $148.5M and $37.9M profits appearing in periods where operating income was negative, suggesting non-operating items drove the reported bottom line.
Net income swinging from a $148.5M gain in 2025Q3 to a $15.2M loss in 2026Q1 while operating losses stayed in a similar range points to large non-operating or one-time items. Reported EPS therefore carries limited information about underlying operating performance. Analysts should treat headline net income as unreliable for valuation until the drivers of these discrete gains are identified.
Bear Case Centers on Unsustained Revenue
The strongest challenge to KYNB's income statement is that the recent revenue recovery, from $1.3M to $3.7M, may not persist, and the company's reported losses could widen if revenue reverts toward the lower end of its range.
Short-seller scrutiny would likely focus on the gap between the 2024 revenue peak and the current run-rate, questioning whether the earlier figures reflected non-recurring activity. With operating losses consistently exceeding $5M per quarter, a return to sub-$2M revenue would leave the cost base poorly covered. Based on reported figures, the absence of a clearly repeatable revenue stream is the central vulnerability in this analysis.